0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Mucin-1

Mucin-1

Mucin-1 Molecule Information

Name:Mucin-1
Target Synonym:Episialin?Polymorphic epithelial mucin?MUC1-alpha?Peanut-reactive urinary mucin?MUC-1?Tumor-associated mucin?MUC1-CT?MUC1-beta?MUC1?Krebs von den Lungen-6?Mucin-1 subunit alpha?Mucin-1 subunit beta?Cancer antigen 15-3?CD_antigen=CD227?Breast carcinoma-ass
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:24
Lastest Research Phase:Phase ?

Mucin-1 Protein Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
MU1-H5252 Human Human Mucin-1 / MUC-1 Protein, Fc Tag
MU1-H5252-structure
MU1-H5252-sds

Mucin-1 Molecule Synonym Name

Mucin 1,MUC1,CD227,EMA,H23AG,KL-6,MAM6,MUC-1/SEC,MUC-1/X,MUC1/ZD,PEM,PEMT,PUM,CA 15-3,Episialin

Mucin-1 Molecule Background

Mucin-1 (MUC1) is also known as Tumor-associated epithelial membrane antigen (EMA), Polymorphic epithelial mucin (PEM), Peanut-reactive urinary mucin (PUM), PEMT, Krebs von den Lungen-6 (KL-6), CD antigen CD227, Episialin, H23AG. MUC1 is a glycoprotein with extensive O-linked glycosylation of its extracellular domain. Mucins line the apical surface of epithelial cells in the lungs, stomach, intestines, eyes and several other organs. Mucins protect the body from infection by pathogen binding to oligosaccharides in the extracellular domain, preventing the pathogen from reaching the cell surface. Except protective function by binding to pathogens, MUC1 also functions in a cell signaling capacity. Overexpression of MUC1 is often associated with colon, breast, ovarian, lung and pancreatic cancers.

Mucin-1 References

Mucin-1 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
MUC1-Poly-ICLC MUC1-poly-ICLC,MUC1 poly ICLC Phase Ⅱ University of Pittsburgh Non small cell lung cancer (NSCLC), Colorectal cancer Details
Monoclonal antibody SM-3 Phase Ⅰ Cancer Research Technology Polycythaemia vera, Solid tumours Details
90Y Clivatuzumab Tetraxetan 90Y-hPAM4; 90hY-PAM4; IMMU-107,90YhPAM4; 90hYPAM4; IMMU107 Phase Ⅲ Immunomedics Pancreatic cancer Details
Cancer vaccine MUC-1 (GlaxoSmithKline/University of Pittsburgh) Phase Ⅰ GlaxoSmithKline, University of Pittsburgh Colon cancer, Breast cancer, Pancreatic cancer Details
Cantuzumab mertansine SB-408075 Phase Ⅰ ImmunoGen Cancer Details
Anti MUC 1 chimeric antigen receptor T cell therapy (Innovative Cellular) Phase Ⅰ Innovative Cellular Therapeutics Breast cancer, Lung cancer, Pancreatic cancer Details
hCTMO1 hCTMO1 Phase Ⅰ Celltech Solid tumours Details
Anti-MUC1 monoclonal antibody (OncoQuest) Anti-MUC1 AR20.5; AR20.5; mAb-AR20.5 Phase Ⅱ AltaRex, OncoQuest, ViRexx Medical Corp Breast cancer, Multiple myeloma (MM), Pancreatic cancer Details
MX-DTPA BrE-3 Phase Ⅰ Nonindustrial source Breast cancer Details
R-1549 Phase Ⅲ Cancer Research UK, Antisoma, Roche Gastric cancer, Ovarian cancer Details
Pankomab GT-MAB-2.5-GEX Phase Ⅱ NEMOD, Glycotope Solid tumours, Ovarian cancer Details
TG-4010 TG-4010; VV-MUC-IL2 Phase Ⅲ Transgene Non small cell lung cancer (NSCLC) Details
Breast cancer vaccine BP1 7 (Biomira) Phase Ⅰ Biomira Breast cancer Details
IMT 504 IMT-504; IMT504 Phase Ⅱ Immunotech Neuropathic pain, Rabies, Diabetes, Chronic lymphocytic leukemia (CLL), Breast cancer, HBV infection, Sepsis, Influenza virus infection, Osteoporosis Details
ONT-10 BGLP-40; L-BGLP40; ONT-10,BGLP40; LBGLP40; ONT10,BGLP 40; LBGLP 40; ONT 10 Phase Ⅰ Cascadian Therapeutics Breast cancer, Solid tumours, Ovarian cancer Details
Adenoviral MUC1 vaccine (Etubics) Ad5 MUC1; ETBX-061 Phase Ⅱ Etubics Corporation Urothelial cancer, Breast cancer, Squamous cell carcinoma of head and neck cancer (SCCHN), Solid tumours, Non-Hodgkin's lymphoma (NHL), Ovarian cancer, Colon cancer, Triple negative breast cancer, Non small cell lung cancer (NSCLC), Merkel cell carcinoma, Prostate cancer, Colorectal cancer, Lung cancer, Squamous cell cancer, Melanoma Details
GO-2032c GO-203-2C Phase Ⅱ Genus Oncology, Dana-Farber Cancer Institute Acute myeloid Leukemia (AML) Details
Anti-PEM monoclonal antibody Phase Ⅱ Access Pharmaceuticals Breast cancer Details
Anti-PD-L1/MUC1 CAR-pNK cell therapy (PersonGen Biomedicine/Anke Biotechnology) CAR-pNK,CAR pNK Phase Ⅱ PersonGen Biomedicine, Anke Biotechnology Solid tumours Details
CMB-401 CMB-401; CDP-671 Phase Ⅱ Celltech Non small cell lung cancer (NSCLC), Ovarian cancer Details
Activated CIK and CD3-MUC1 bispecific antibody Phase Ⅱ Benhealth Biopharmaceutical Breast cancer, Colorectal cancer, Liver cancer, Pancreatic cancer Details
Monoclonal antibody HMFG1 AS-1402; BTH-1704; HuHMFG-1; R-1550 Phase Ⅰ Cancer Research UK, Antisoma Pancreatic cancer Details
BP1-7-KLH BP1-7-KLH; BLP-16 Phase Ⅰ Cascadian Therapeutics Breast cancer Details
Pepscan (Antisoma) AS-109 Phase Ⅱ Antisoma Breast cancer Details

This web search service is supported by Google Inc.

totop